PYC Therapeutics (ASX:PYC) Releases Q2 2025 Shareholder Update
Clinical Progress
PYC Therapeutics has advanced all four drug development programs through key milestones in Q2 2025. The company initiated dosing in its Phase 1a/1b clinical trial and completed dosing in cohorts 1 and 2 of the Single Ascending Dose (SAD) study for Polycystic Kidney Disease (PKD) drug candidates. Additionally, PYC presented clinical proof of concept data for Retinitis Pigmentosa type 11 (RP11) and aligned with the FDA on the framework for a registrational trial. For the second blinding eye disease, Autosomal Dominant Optic Atrophy (ADOA), PYC completed dosing in patient cohort 2 in the SAD study and gained approval to escalate dosing to the third and final cohort in this Phase 1 clinical trial. For Phelan-McDermid Syndrome (PMS), pre-clinical data supporting progression to human trials were presented.
Financial Update
Following a successful $146 million capital raise in Q1 CY25, PYC Therapeutics extends its cash runway to over $200 million into CY27. As of June 30, 2025, the company holds $153 million in cash, with an additional $20 million expected from R&D rebates in H2 CY25. Research and development expenditures continue to support ongoing clinical studies and discovery programs.
Future Outlook
In the second half of CY25, PYC expects to complete the dose escalation study for PKD, initiate registrational trials, and present updated data from ongoing RP11 trials. For ADOA, progression to a Multiple Ascending Dose (MAD) study and early data presentations are anticipated. PMS programs will commence GLP toxicology studies in preparation for human trials in 2026. All four programs are on track to achieve significant milestones, positioning PYC towards becoming a commercial-stage company.
Motley Fool contributor Lauren Surplice has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
